Skip to main content

8 Result(s)

within T Caravita Remove this filter Medicine/Public Health, general Remove this filter

and

  1. No Access

    Article

    Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis

    In newly diagnosed myeloma patients, upfront autologous transplant (ASCT) prolongs progression-free survival 1 (PFS1) compared with chemotherapy plus lenalidomide (CC+R). Salvage ASCT at first relapse may stil...

    F Gay, S Oliva, M T Petrucci, V Montefusco, C Conticello, P Musto, L Catalano… in Leukemia (2017)

  2. No Access

    Article

    A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma

    This phase 2 trial evaluated three low-dose intensity subcutaneous bortezomib-based treatments in patients ⩾75 years with newly diagnosed multiple myeloma (MM). Patients received subcutaneous bortezomib plus o...

    A Larocca, S Bringhen, M T Petrucci, S Oliva, A P Falcone, T Caravita… in Leukemia (2016)

  3. No Access

    Article

    Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia

    P Musto, V Simeon, M C Martorelli, M T Petrucci, N Cascavilla, F Di Raimondo… in Leukemia (2014)

  4. No Access

    Article

    Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapy

    Lenalidomide has raised concerns regarding its potential impact on the ability to collect stem cells for autologous stem cell transplantation, especially after prolonged exposure. The use of cyclophosphamide p...

    F Cavallo, S Bringhen, G Milone, D Ben-Yehuda, A Nagler, E Calabrese… in Leukemia (2011)

  5. No Access

    Article

    High-dose therapy with autologous PBSC transplantation in the front-line treatment of Waldenstrom's macroglobulinemia

    T Caravita, A Siniscalchi, A Tendas, L Cupelli, T Dentamaro… in Bone Marrow Transplantation (2009)

  6. No Access

    Article

    Vasculogenic mimicry by bone marrow macrophages in patients with multiple myeloma

    Bone marrow macrophages of patients with active and nonactive multiple myeloma (MM), monoclonal gammopathies of undetermined significance (MGUS) and benign anemia (controls) were stimulated for 7 days with vas...

    C Scavelli, B Nico, T Cirulli, R Ria, G Di Pietro, D Mangieri, A Bacigalupo… in Oncogene (2008)

  7. No Access

    Article

    Multiple myeloma: comparison of two dose-intensive melphalan regimens (100 vs 200 mg/m2)

    Several trials have shown the superior impact of high-dose melphalan (usually 200 mg/m2, MEL200) vs standard therapy in myeloma patients. Intermediate-dose melphalan (100 mg/m2, MEL100) is also superior to the st...

    A Palumbo, S Bringhen, A Bertola, F Cavallo, P Falco, M Massaia, B Bruno, C Rus… in Leukemia (2004)

  8. No Access

    Article

    Enumeration of CD34+ hematopoietic progenitor cells for clinical transplantation: comparison of three different methods

    Three different methods for determination of CD34+ cells in G-CSF-mobilized peripheral blood were compared. The methods were: the Milan/Mulhouse protocol, the ISHAGE guidelines for CD34+ cells enumeration and our...

    A Venditti, A Battaglia, G Del Poeta, F Buccisano… in Bone Marrow Transplantation (1999)